Hydroxychloroquine Blood Level Range Defined for Lupus Treatment

Rheumatologists managing systemic lupus erythematosus faced a persistent clinical challenge: how to dose hydroxychloroquine safely. Standard clinical practice relies on body weight to calculate a daily regimen. Yet that metric often fails to reflect how individual bodies absorb, metabolize, and clear the medication.

To address those gaps, an observational study examined data from patients enrolled in the Systemic Lupus International Collaborating Clinics who underwent hydroxychloroquine blood level measurements. The analysis included 1,842 patients and sought to define the upper blood concentration threshold associated with drug-related toxicity.

Defining the Therapeutic Window for Systemic Lupus Erythematosus

The findings, published in Arthritis & Rheumatology and reported in January 2026, identify a specific therapeutic window for whole-blood drug concentration between 750 ng/mL and 1,150 ng/mL. Maintaining concentrations within this bracket helps prevent active disease flares while guarding against severe complications.

“Currently, hydroxychloroquine is dosed based on body weight.”

Shivani Garg, MD, PhD, medical director of the University of Wisconsin-Madison Lupus and Lupus Nephritis Clinics

According to Shivani Garg, MD, PhD, weight-based calculations create notable clinical vulnerabilities. Doses above 5 mg/kg correlate with a two-fold increase in retinopathy risk, whereas dropping below that threshold is associated with a six-fold higher flare risk. Furthermore, weight metrics ignore critical physiological variables such as drug clearance, metabolic rate, and medication interactions.

“Moreover, weight-based dosing does not account for several factors such as metabolism, clearance, absorption and interactions, which can all affect blood and tissue levels, and produce heterogeneity in clinical response.”

Shivani Garg, MD, PhD, associate professor at the University of Wisconsin School of Medicine and Public Health

Previous investigations into blood concentrations and disease control have pointed toward similar thresholds. Research measuring drug levels in lupus patients demonstrated a trend linking higher disease activity and lower HCQ levels, noting that concentrations greater than 500 ng/mL could be regarded as the critical value for drug effectiveness.

Identifying Subpopulations Vulnerable to Supratherapeutic Exposure

When researchers evaluated toxicity risk using adjusted spline and logistic regression models, approximately 4.9% of patients exhibited hydroxychloroquine-related toxicity. Odds of experiencing toxic effects increased by 2.1-fold when blood levels reached or exceeded 1,150 ng/mL. Crucially, the data revealed a saturation point in therapeutic effect at that exact upper boundary, indicating that concentrations beyond 1,150 ng/mL provide no additional risk reduction for SLE Disease Activity Index 2000 (SLEDAI-2K 6) while significantly escalating harm.

Vulnerability is not distributed evenly across all patients. Individuals managing chronic kidney disease face distinct pharmacological hurdles. Patients with stage 3 chronic kidney disease or above were 2.3 times more likely to develop supratherapeutic levels.

“Also, certain subpopulations, such as those with chronic kidney disease stage 3 and above, would benefit from close monitoring of hydroxychloroquine blood levels to guide safe reductions at the individual patient level to balance safety and efficacy, given more than 47% of patients had supratherapeutic — aka toxic — levels despite weight-based dosing.”

Shivani Garg, MD, PhD, medical director of the University of Wisconsin-Madison Lupus and Lupus Nephritis Clinics

Arbitrarily lowering doses in kidney disease patients risks triggering severe lupus flares, yet maintaining standard dosing accelerates toxicity. The researchers suggest that direct blood monitoring offers a safer path forward for patients with renal impairment, allowing physicians to make precise adjustments rather than relying on generalized formulas.

Balancing Ocular Safety with Systemic Disease Management

The relationship between blood concentrations and retinal health remains a subject of ongoing clinical examination. While some prospective cohort studies indicate that average and peak blood levels help predict retinal lesions, other analyses suggest that cumulative drug dose and total treatment duration remain the optimal predictors of ocular toxicity.

Retinal lesions represent the most common form of hydroxychloroquine-induced ocular toxicity, though the overall incidence after long-term use remains low. A retrospective case-control study involving 2,361 patients who maintained continuous therapy for at least four years found a total retinopathy incidence rate of 7.5% when evaluated using SD-OCT.

To safeguard patients while preserving therapeutic benefits, clinical experts advocate for integrating direct blood level assessments into routine care.

“Hydroxychloroquine blood level monitoring should be used in all patients with lupus to guide safe and effective use of hydroxychloroquine and optimal/precise dosing.”

Shivani Garg, MD, PhD, associate professor at the University of Wisconsin School of Medicine and Public Health

This approach ensures that medication levels remain within a safe range to minimize the risk of toxicity while maximizing the long-term therapeutic outcomes for those living with lupus.